Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Esperion ( (ESPR) ) just unveiled an announcement.
On July 1, 2025, Esperion announced the appointment of Craig Thompson, CEO of Cerevance, to its Board of Directors, expanding the board to eight members. Thompson’s extensive experience in biopharmaceutical leadership is expected to enhance Esperion’s strategic direction as it continues to innovate in cardiovascular and cardiometabolic drug development, potentially impacting its market position and stakeholder interests.
The most recent analyst rating on (ESPR) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Esperion stock, see the ESPR Stock Forecast page.
Spark’s Take on ESPR Stock
According to Spark, TipRanks’ AI Analyst, ESPR is a Neutral.
Esperion’s overall stock score reflects significant financial risks due to negative profitability and high leverage, despite strong revenue growth and positive sentiment from recent corporate events and earnings call. Technical indicators suggest potential for rebound, but valuation remains a concern.
To see Spark’s full report on ESPR stock, click here.
More about Esperion
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing and commercializing oral, non-statin medicines for patients at risk of cardiovascular disease. The company is known for its FDA-approved therapies targeting elevated low-density lipoprotein cholesterol (LDL-C) and is advancing its pipeline with ATP citrate lyase inhibitors (ACLYi).
Average Trading Volume: 5,164,958
Technical Sentiment Signal: Sell
Current Market Cap: $196.9M
Learn more about ESPR stock on TipRanks’ Stock Analysis page.